The increasingly acrimonious battle between Endurance Specialty and Aspen Insurance – sparked by an unsolicited $3.2 billion bid for Aspen by Endurance – took a new twist late last week when Aspen moved to block the bid through a shareholders’ rights plan, which Endurance described as a “poison pill”.
To continue reading, you need a subscription to Intelligent Insurer.
If you have already subscribed please login.
If you have any technical issues please contact support.
Aspen Insurance, Endurance Specialty, Shareholders' Rights Plan, Michael McGuire
